Breast cancer second-line treatment patterns in China
Part of Cancer, Skin clinical trials.
This study looks at how doctors in China treat hormone receptor-positive, HER2-negative breast cancer that has spread, when patients are starting their second line of therapy. The goal is to learn more about real-world treatment patterns and results, which may help you and your doctor make more informed treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have breast cancer that has spread to other parts of the body or cannot be removed with surgery.
- Your breast cancer is hormone receptor-positive and HER2-negative (this is often on your pathology report).
- You are about to start your second line of treatment, or you have already started it within the last 2 months.
- You are not planning to join a blinded clinical trial for this treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study observes how doctors treat early breast cancer and what outcomes patients have. It's for people with hormone receptor-positive, HER2-negative breast cancer that hasn't spread to many lymph nodes.
This trial looks at how well a standard “neoadjuvant” treatment plan works in real-world patients. It is for people newly diagnosed with stage II–III HR+ breast cancer and aims to see whether treatment gives expected outcomes in everyday care.
This study looks at how well Trastuzumab Deruxtecan (T-DXd) works in Chinese women with breast cancer that has spread. It is for people whose cancer is either HER2-positive or HER2-low and who have already had some treatment.
This trial is looking at how neratinib is used as extended treatment after early-stage HER2+ breast cancer, and how it affects patient outcomes in real-world care. You might qualify if you’re an adult with HER2+ early breast cancer that doctors consider free of recurrence and metastasis, and you’re able to take neratinib as prescribed in China.
This trial tests whether switching between two targeted therapy combinations can help women with HER2-positive advanced breast cancer that has progressed after previous treatments. It aims to find a new effective option for people who have already tried one or two lines of therapy.
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.